A new report from the American Lung Association highlights a persistent gap in lung cancer screening across the United States. According to the report, only a tiny fraction of eligible Americans undergo the recommended screening for lung cancer, even though the disease accounts for 20% of all cancer-related deaths in the country. The findings underscore a critical missed opportunity for early detection and improved outcomes.
The report notes that while screening rates remain low, there has been a notable improvement in lung cancer survival rates. Between 2015 and 2019, the five-year survival rate for lung cancer increased to 26.6%. This progress is attributed to advances in research and novel treatments, including efforts by companies such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are focused on developing innovative therapies.
The American Lung Association emphasizes that increasing screening adherence could significantly reduce lung cancer mortality. Early detection through low-dose computed tomography (LDCT) scans can identify cancers at more treatable stages. However, barriers such as lack of awareness, limited access to healthcare, and insufficient physician recommendations continue to hinder screening uptake.
This report is part of ongoing efforts by organizations like the American Lung Association to track and improve lung cancer outcomes. The data serves as a call to action for healthcare providers, policymakers, and the public to prioritize lung cancer screening. With continued investment in research and public health initiatives, the goal is to further raise survival rates and reduce the burden of lung cancer in the United States.
